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Background: Trimethoprim-sulfamethoxazole (TMP-SMX) is an antimicrobial drug 
combination commonly prescribed in children and adults. The study objectives were 
to validate and apply an HPLC–MS/MS method to quantify TMP-SMX in dried plasma 
spots (DPS) and dried urine spots (DUS), and perform a comparability analysis with 
liquid matrices. Results: For TMP the validated range was 100–50,000 ng/ml for DPS 
and 500–250,000 ng/ml for DUS; for SMX, the validated range was 1000–500,000 ng/ml 
for both DPS and DUS. Good agreement was noted between DPS/DUS and liquid 
plasma and urine samples for TMP, while only modest agreement was observed for 
SMX in both matrices. Conclusion: A precise, accurate and reproducible method was 
developed to quantify TMP-SMX in DPS and DUS samples.
Trimethoprim-sulfamethoxazole 
(TMP-SMX) is a combination of two 
antimicrobial agents that inhibit distinct 
proteins in the tetrahydrofolate synthesis 
pathway; TMP inhibits the enzyme dihy-
drofolate reductase and disrupts production 
of tetrahydrofolic acid, whereas SMX mim-
ics para-aminobenzoic acid and prevents 
its conversion to dihydrofolic acid via dihy-
dropteroate synthetase [1]. Inhibition of these 
proteins affects DNA bacterial synthesis and 
ultimately bacterial growth. When admin-
istered together, this drug combination has 
potent activity against aerobic gram-positive 
and gram-negative bacteria. In children and 
adults, TMP-SMX is prescribed to treat uri-
nary, respiratory or GI tract infections [1]. 
Also, it is commonly prescribed to treat 
skin and skin structure infections caused by 
methicillin-resistant Staphylococcus aureus [2].
Simultaneous quantification of TMP-
SMX in biological fluids has been performed 
using HPLC [3–7], HPLC–MS/MS [7,8] and 
capillary zone electrophoresis [9]. Often 
these methods have been applied to simul-
taneously quantify TMP-SMX in human 
plasma samples collected in adult PK stud-
ies. In pediatric PK studies, because of 
practical limitations regarding the number 
and volume of blood samples that can be 
collected ethically, dried blood spot (DBS) 
sampling and multidrug assays have been 
proposed as novel tools to improve pedi-
atric clinical trial designs [10]. The advan-
tages of DBS sampling include significantly 
reduced blood volumes (10–25 μl), reduced 
biohazard risk, ease of storage (room tem-
perature) and improved drug stability [11]. 
Measurement of drug concentrations in 
dried plasma spots (DPS) [12–14] and, less 
commonly, in dried urine spots (DUS) 
also have been reported [15]. However, mea-
surement of TMP-SMX in DPS and DUS 
samples has not been reported previously, 
and measurement of drug concentrations in 
dried matrix samples in children often has 
focused on using DBS. Drug measurement 
in DPS samples has the additional advan-
tage of avoiding the effect of varying hema-
tocrit on sample homogeneity observed with 
DBS [16] and allows for easy reporting of 
results as the PK literature frequently focuses 
on plasma concentrations [12].
The objective of the analyses described 
herein was to develop and validate an 
HPLC–MS/MS method for the simultane-
ous quantification of TMP-SMX in DPS and 
DUS samples collected in an opportunistic 
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pediatric PK study. Clinical samples were then ana-
lyzed and a comparability analysis of the dried and 
liquid matrix samples was performed.
Experimental
Materials
Free base forms of the study compounds TMP 
(CAS No. 738–70–5, Batch SZB9352XV) and SMX 
(CAS No. 723–46–6, Batch SZBC124XV) were 
purchased from Sigma-Aldrich Corporation (MO, 
USA) (Figure 1). Stable isotope-labeled forms of the 
study drugs were used as IS (CDN Isotopes, Inc., 





]-SMX (Lot: M237P19). Control 
K2 EDTA human plasma (BioChemed Services, VA, 
USA) and urine (collected from human volunteers) 
was centrifuged for approximately 5 min at 4000 rpm 
prior to use. Whatman® FTA® DMPK-C were used 
for the DPS analysis and Whatman® FTA® DMPK-
C IND dried matrix spotting cards were used for 
DUS analysis (Whatman Ltd Co., Middlesex, UK; 
GE Healthcare, NJ, USA Catalog No. WB120224).
Standard solutions
For the calibration standards, eight concentration lev-
els were prepared for both TMP and SMX in human 
plasma and urine: 100–50,000 ng/ml in human 
plasma for TMP; 500–250,000 ng/ml in human urine 
for TMP and 1000–500,000 ng/ml in human plasma 
and urine for SMX. The following nominal concen-
trations were prepared for QC samples for TMP/
SMX in human plasma: 100/1000 (LLOQ and car-
ryover assessments only), 300/3000, 4000/40,000, 
40,000/400,000 and 100,000/1,000,000 (dilu-
tion linearity assessment only) ng/ml. In human 
urine, the following TMP/SMX concentrations were 
selected for QC samples: 500/1000 (LLOQ and car-
ryover assessments only), 1500/3000, 20,000/40,000, 
200,000/400,000 and 500,000/1,000,000 (dilution 
linearity assessment only) ng/ml.
For DPS analysis, stock solutions were prepared by 
accurately weighing the appropriate amount of TMP/
SMX to dissolve in 1:1 (v/v) methanol: dimethyl sulf-
oxide to obtain 4 mg/ml and 40 mg/ml stock solu-
tions of TMP and SMX, respectively. A combined 
stock solution was then prepared by combining equal 
volumes of each, resulting in a 2 mg/ml TMP and 20 
mg/ml SMX solution. For DUS analysis, a similar pro-
cedure was followed, and a combined stock solution 
containing 10 mg/ml TMP and 20 mg/ml SMX was 
obtained. The stock solutions were stored at -70°C or 
below. Calibration standards and QC samples were 
made from these stock solutions.
Calibration standards and QC samples were pre-
pared using human plasma or human urine that was 
thoroughly mixed, spotted on dried matrix spotting 
Key terms
Trimethoprim: Bacteriostatic antimicrobial agent belonging 
to the dihydrofolate reductase inhibitor drug class.
Sulfamethoxazole: Bacteriostatic sulfonamide 
antimicrobial agent.
Dried plasma spots: Sampling method whereby plasma is 
spotted on a collection card.
Dried urine spots: Sampling method whereby urine is 
spotted on a collection card.
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cards and then dried. Calibration standards were 
extracted fresh daily. A 10 μl volume per spot was used, 
except for QCs that were prepared to test the effects of 
varying spot volume (5 and 15 μl). Calibrated mechan-
ical pipets were used for all volumetric measurements. 
Calibration curves and QC samples were dried over-
night on the bench top and then in a Minigrip zippered 
bag with desiccant for 24 h prior to use.
Extraction method
Initially, 3 mm punches were used for the dried matrix 
sample analysis. However, analysis of 3 mm punches 
from the center and edge of punches indicated that the 
TMP and SMX concentrations on the spot were not 
homogeneous. Therefore, a 6 mm punch was used to 
sample the majority of the spot and minimize nonho-
mogeneity issues. Methanol has been widely used as an 
extraction solvent for dried matrix sample analysis due 
to its ability to provide a relatively clean extract by both 
binding biological matrix to the filter paper on the dried 
matrix spot card and solubilizing the analyte. Extrac-
tion volumes of 100, 200 and 400 μl were tested for 
extraction volumes. The 400 μl volume provided the 
best extraction efficiency. The final extraction method 
involved punching a 6 mm spot into a microcentrifuge 
vial, adding 400 μl of IS in methanol, and vortexing for 
5 min. Samples were then centrifuged at 13,000 rpm for 
5 min. An aliquot (50 μl) of each sample was added to a 
96-well plate containing 50 μl of deionized water.
Liquid plasma & urine method sample 
preparation
An aliquot of sample (10 μl) was added to a sample 
container. IS in methanol (70 μl) was added to each 
sample. Samples were then vortexed for 5 min and 
centrifuged at 4000 rpm for 10 min. Sample (25 μl) 
was then added to a 96-well plate containing 75 μl 
of deionized water and analyzed using a C8 HPLC 
column and MS/MS.
HPLC–MS/MS
A detailed description of the equipment and settings is 
provided in Table 1. The Agilent 1200 series HPLC sys-
tem and Agilent 1290 autosampler were used (Agilent 
Technologies, Inc., CA, USA). The ACE PFP, 2.1 × 50 
mm, 3 μm (Advanced Chromatography Technologies 
Ltd, Aberdeen, Scotland) analytical column was used. 
The column temperature was 30°C. The injection vol-
ume, flow rate and run time were 10 μl, 0.75 ml/min 
and 3.5 min, respectively. A gradient mobile phase was 
used: water containing 0.1% (v/v) formic acid (mobile 
phase A) and acetonitrile containing 0.1% (v/v) formic 
acid (mobile phase B). During the first 3 min, the per-
centage mobile phase B increased from 5 to 45%; from 
3.01–3.4 min, it was 100% B; and for the remainder of 
the run time (3.41–3.5 min), it was 5% B. The HPLC 
system was coupled with an Agilent 6460 series Triple 
Quadrupole system (Agilent Technologies, Inc., CA, 
USA). The Agilent Mass Hunter software was used for 
data acquisition and quantitative analysis. A positive 
mode electrospray ionization interface was used. The 
following system settings were used: 350°C, gas tem-
perature; 10 l/min, gas flow; 50 psi, nebulizer pressure; 
10.1 l/min, sheath gas flow, 4000 V capillary voltage; 
140/160 V TMP/SMX, fragmentor values and 25/15 
V TMP/SMX, collision energy values.
Liquid plasma and urine concentrations were 
measured using validated HPLC–MS/MS methods. 
Table 1. Description of equipment and settings.
HPLC MS/MS
Autosampler Agilent 1260 Mass spectrometer Agilent 6460 series quadrupole
Injection volume 10 μl Ionization interface Positive mode electrospray, Jet 
stream
Chromatography system Agilent 1200 series Gas temperature 350ºC
Flow rate 0.75 ml/min Gas flow 10 l/min
Analytical column Ace PFP, 2.1 × 50, 3.0 μm Nebulizer pressure 50 psi
Column temperature 30ºC Sheath gas temperature 350ºC
Run time/Data acquisition time 3.5 min/ 3.5 min Sheath gas flow 10.1 l/min
Mobile phase A Water containing 0.1% (v/v) 
formic acid
Capillary voltage 4000 V
Mobile phase B Acetonitrile containing 
0.1% (v/v) formic acid
Fragmentor value 160 V (sulfamethoxazole), 140 V 
(trimethoprim)
Injector wash 70:30 MeOH:Water CE value 15 V (sulfamethoxazole), 25 V 
(trimethoprim)
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The Agilent 1200 Series HPLC system, Agilent 6410 
Series Triple Quadrupole mass spectrometer and Agi-
lent Zorbax XDB-C8 analytical column (2.1 mm 
internal diameter × 30 mm length, 3.5 μm particle 
size) were used (Agilent Technologies). A gradient 
mobile phase was made up of water containing 0.1% 
(v/v) formic acid and methanol containing 0.1% (v/v) 
formic acid. The method was validated according to 
the standards set forth by the US FDA [17].
The dried matrix spot and liquid methods were 
independently developed and validated by two differ-
ent analysts. The dried matrix spot methods were run 
on a more sensitive HPLC–MS/MS system because 
more sensitivity was needed. An explanation for this 
could be that less volume is in a 6 mm punch (about 5 
μl) compared with the 10 μl of liquid sample used. The 
HPLC system is different only because the HPLCs 
were already configured with the respective mass 
spectrometers that were used.
Method validation
The analytical methods were validated according to 
standards set forth by the FDA [17]. For both DPS and 
DUS samples, validation included assessment of stan-
dard curve fitting, specificity, within- and between-run 
accuracy and precision, recovery, matrix effect, linear-
ity of dilutions, carryover, punch carryover, sample 
volume variation, reproducibility and stability. For the 
latter, bench-top and postpreparative stability results 
are reported herein.
Specificity was assessed by analysis of samples pre-
pared from human plasma and urine (six different lots 
each). The method was deemed specific if blank TMP 
and SMX responses in DPS and DUS samples were 
≤20% of the average response at the LLOQ.
Recovery was assessed at three concentrations (low, 
middle, and high) by comparing extracted QC samples 
to unextracted QC samples that were prepared by spiking 
blank matrix postextraction. Matrix effect was evaluated 
by comparing extracted and spiked solvent QC samples. 
Carryover was assessed by comparing five replicate injec-
tions of the lowest calibration standard followed by five 
replicate injections of the lower level calibration standard 
that had each been injected after an ULOQ standard. 
In addition, punch carryover was assessed by evaluating 
analyte response with a blank DPS or DUS card that was 
punched immediately following punching of a card con-
taining the ULOQ. To assess the linearity of dilutions, 
DPS and DUS samples that were two-times greater than 
the ULOQ were prepared and diluted ten-times with 
dried plasma or urine spot extract for analysis. Five rep-
licates were made for each matrix. Sample volume varia-
tion was evaluated by spotting mid-concentration QCs 
using a volume less (5 μl) and greater (15 μl) than the 
validated spot volume of 10 μl. Five replicates were used 
for each sample volume.
To assess storage stability, low and high QC samples 
were stored at room temperature in Minigrip zippered 
bags with desiccant for two or 8 days for DPS samples 
and two or 14 days for DUS samples. Postpreparative 
stability for DPS samples was assessed by injecting 
extracted QC samples (low and high QCs in replicates 
of five) stored at room temperature for one and 9 days 
with fresh extracts of calibration standards. Similarly, 
extracted DUS QC samples (low and high QCs in rep-
licates of five) were stored in the autosampler at room 
temperature for 4 days and injected with a fresh cali-
bration curve. Samples were deemed stable if the mean 
values had an accuracy of within ± 15% (i.e., 85–115%) 
and precision did not exceed a coefficient of variation 
of 15%.
Opportunistic pediatric study
DPS and DUS clinical samples were collected from 
pediatric patients enrolled in the Pharmacokinetics 
of Understudied Drugs Administered to Children 
per Standard of Care (POPS) trial [18], a multicenter 
(n = 26), prospective, PK and safety study in children 
(<21 years of age). Children who received one of the 
targeted drugs of interest (including TMP-SMX) per 
standard of care as administered by their treating care-
giver were eligible for enrollment [19]. Exclusion crite-
ria included failure to obtain consent/assent or known 
pregnancy. PK samples were collected either at the 
time of routine clinical laboratory collections or, if the 
parent/patient consented, at a specific collection time 
for study purposes. Because this was a standard-of-care 
study, dosing and PK sample collection times varied 
between subjects.
Whole blood samples of 200–2000 μl were collected 
based on the participant’s age and weight. DPS samples 
were collected as an aliquot of liquid plasma samples. 
After plasma was separated via centrifugation ([2000 
g] for 10 min at 4°C), a 10 μl micropipette was used to 
measure 10 microliters per spot, and two plasma spots 
were spotted per card. The cards were allowed to dry 
for at least 2 h at room temperature. The card was then 
sealed tightly with two desiccant packs and a humidity 
indicator card in a gas impermeable (Minigrip) bag. 
The cards were stored and shipped desiccated at ambi-
ent temperature. A similar procedure was followed for 
DUS samples using an aliquot of urine.
Data analysis
For calibration standards, a plot of the analyte-to-IS 
peak area ratio versus analyte concentrations was cre-
ated. A weighted (1/x2) power regression analysis was 
applied to the data. The concentrations of the analytes 
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in the QC samples were determined using the respec-
tive calibration line; then, the accuracy and precision 
of the method was assessed.
An analysis was performed to compare DPS and 
DUS TMP and SMX concentrations against the estab-
lished methods of analysis, liquid plasma (LPS) and 
liquid urine (LUS), respectively. The ratio of DPS to 
LPS samples (and DUS to LUS) was computed for 
each drug and plotted against the average concentra-
tion for each paired sample. Passing-Bablock regres-
sion analysis was used to characterize potential bias 
between matrices, with dried matrices plotted on the 
y-axis, and liquid matrices plotted on the x-axis as the 
reference standard. A Passing-Bablock regression is a 
nonparametric alternative to ordinary linear regression 
that assumes a constant ratio of variances, and is less 
sensitive to outliers when compared with other regres-
sion methods [20]. The presence of a systematic and/
or proportional bias was noted if the y-intercept and/
or regression slope significantly differed from zero and 
unity, respectively [21,22]. Bias also was assessed through 
calculation of the median percentage prediction error 
(MPPE), while imprecision was evaluated through cal-
culation of the median absolute percentage prediction 
error (MAPE). Calculations of MPPE and MAPE were 
as follows:


















 denote the drug concentrations in 
DPS and LPS, respectively. Similar equations were 
used to calculate MPPE and MAPE for DUS and LUS 
samples. A value of <15% for MPPE or MAPE was 
considered acceptable [22–24].
STATA 13 (TX, USA) was used for statistical analy-
ses, and MedCalc Statistical Software version 14.8.1 
(Ostend, Belgium) was used to generate Passing-
Bablock regression plots. Standard summary statistics 
were used to describe the demographics and laboratory 
characteristics of the study population.
Results & discussion
Standard curve fitting
Linear responses (using a power regression) in the TMP/
IS peak area ratios were observed over the range of 100–
50,000 ng/ml for DPS and 500–250,000 ng/ml for DUS 
samples. Also, linear responses (using a power regression) 
in the SMX/IS peak area ratios were observed over the 
range of 1000–500,000 ng/ml for DPS and DUS sam-
ples. The correlation coefficients were 0.995 or better 
for all runs. Accuracy values were within ± 15% of the 
theoretical value for all runs at all concentration levels. 
Representative calibration plots for SMX and TMP in 
DPS and DUS are shown in Supplementary Figures 1 & 2. 
Representative chromatograms of LLOQ samples for 
TMP/SMX in DPS and DUS samples are shown in 
Supplementary Figure 3. Zero (IS added) and blank 
(no IS) samples were included with each validation run 
(Supplementary Figures 4 & 5).
Specificity
The characteristic precursor [M+H]+to product ion tran-
sitions, m/z 291 to 230 and 294 to 123 for TMP and its 
IS, and m/z 254 to 156 and 258 to 160 for SMX and its 
IS, were used as multiple reaction monitoring transitions 
to ensure that optimal selectivity was obtained. For TMP 
IS, the 294→123 transition was used because when we 
performed the compound optimization, the 123 daugh-
ter ion was more abundant and gave us more signal than 
the 230 daughter ion. The method was deemed to have 
adequate specificity based on the analysis of TMP and 
SMX responses in blank samples from six different lots 
(blank responses ≤20% average response at the LLOQ). 
No unacceptable interferences at the retention times 
of TMP, SMX and the IS in DPS or DUS were noted 
with zero or blank samples. The response observed with 
LLOQ samples was assessed in three validation runs for 
both DPS and DUS samples. The following criteria were 
met for the LLOQ samples: the analyte response was at 
least five-times the response obtained with blank sam-
ples (i.e., S/N ratio ≥5); peak response had a precision 
(i.e., CV) of ≤20% and accuracy was between 80 and 
120% of the theoretical value.
Within- & between-run accuracy & precision
Mean within- and between-run accuracy and precision 
values for TMP-SMX DPS and DUS QC samples are 
shown in Tables 2 & 3, respectively. Accuracy was within 
± 15% of the theoretical value for all runs. Precision did 
not exceed 15% for any run.
Recovery, matrix effect & linearity of dilutions
Recovery of TMP and SMX in DPS and DUS samples 
was consistent and reproducible (Table 4). No matrix 
effect was noted through comparison of the percent 
recovery observed in extracted QCs with that in spiked 
solvent samples (100% recovery). Dilution validation 
samples also met acceptance criteria based on accuracy 
and precision.
Carryover & sample volume variation
No carryover was noted for TMP and SMX in DPS and 
DUS samples when the lower level calibration standard 
was injected following injection of the ULOQ (five 
replicates each). When punch carryover was assessed, 
analyte response for blank samples was >20% of the 
mean LLOQ response, and thus the test failed. Punch 
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carryover was then reassessed by use of three cleans-
ing punches (using W903 paper) in between punching 
of the double blank samples. This resulted in a blank 
response <20% of the mean LLOQ response. Spot 
homogeneity was assessed for each matrix using a 3 
mm punch size. Due to variability in the results, it was 
determined that a 6 mm punch must be used to sample 
the majority of the spot and minimize nonhomogeneity 
issues. Last, to assess sample volume variation, 5 and 15 
μl spot volumes were compared with the validated spot 
volume (i.e., 10 μl). Accuracy and precision criteria were 
met for the ten and 15 μl, but not for the 5 μl (116.3%).
Stability
TMP and SMX were stable in DPS when stored at 
room temperature for 6 days. In DUS, both mole-
cules were stable at room temperature for 12 days. 
Postpreparative stability results indicated that pro-
cessed DPS samples are stable for at least 9 days at 
room temperature. Processed DUS samples were 
stable for at least 4 days at room temperature. The 
differences noted between DPS and DUS samples do 
not reflect actual differences in stability, but instead 
are a result of the length of time at which the stability 
was tested.
Comparability analysis
TMP and SMX concentrations measured in LPS and 
LUS were compared graphically with observations in 
DPS and DUS samples, respectively (Figures 2 & 3).
DPS-to-LPS analysis
Forty-seven LPS and DPS paired samples were col-
lected from 34 subjects (median [range] age, 6.9 years 
[0.2, 20.1]; weight, 26.1 kg [4.7, 139.4]; TMP dosing, 
3.0 mg/kg/dose [0.6, 8.8] and 3.2 mg/kg/day [0.6, 
17.6]; SMX dosing, 13.8 mg/kg/dose [3.1, 44.0] and 
16.2 mg/kg/day [3.1, 88.1]). Four paired TMP samples 
were below the LOQ.
The mean TMP DPS to LPS ratio was 0.88 
(95% CI: 0.84, 0.92), and the limits of agreement 
were 0.63 and 1.13. Passing-Bablock regression 
showed linear correlation between the TMP DPS 
and LPS concentrations, and exhibited negligible 
Table 2. Precision and accuracy for dried plasma spots.
 QC sample Trimethoprim Sulfamethoxazole
 Intra-run accuracy (%) Intra-run precision (%) Intra-run accuracy (%) Intra-run precision (%)
Run 1
LLOQ 94.0 2.8 89.3 5.3
Low 91.6 2.8 86.4 3.9
Mid 96.6 0.8 91.6 2.0
High 95.5 2.8 90.2 4.7
Run 2
LLOQ 93.6 3.7 89.9 5.7
Low 92.3 3.7 88.3 3.7
Mid 99.5 2.1 97.1 1.9
High 95.6 2.0 89.9 3.0
Run 3
LLOQ 92.6 1.6 88.3 6.2
Low 95.4 1.7 93.3 2.1
Mid 96.4 2.5 93.0 3.7
High 94.2 2.7 90.4 1.6
QC sample Inter-run accuracy (%) Inter-run precision (%) Inter-run accuracy (%) Inter-run precision (%)
LLOQ 93.4 2.7 89.2 5.4
Low 93.1 3.2 89.4 4.5
Mid 97.5 2.4 93.9 3.6
High 95.1 2.4 90.2 3.1
Trimethoprim: LLOQ, 100 ng/ml; low, 300 ng/ml; mid, 4 μg/ml; high, 40 μg/ml.
Sulfamethoxazole: LLOQ, 1 μg/ml; low, 3 μg/ml; mid, 40 μg/ml; high, 400 μg/ml.
Accuracy and precision were assessed using five determinations per concentration.
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proportional and systematic biases between the two 
matrices (slope 0.93 [95% CI: 0.91, 0.97]; intercept 
-0.04 [95% CI: -0.07, -0.02]). The MPPE for the 
comparison of TMP DPS to LPS concentrations was 
-11.7% and the MAPE was 12.1%.
The mean SMX DPS to LPS ratio was 0.81 (95% CI: 
0.77, 0.86), and limits of agreement were 0.51 and 
1.12. The Passing-Bablock regression showed modest 
agreement between the SMX LPS and DPS concen-
trations (slope 0.86 [95% CI: 0.80, 0.92]; intercept 
-0.76 [95% CI: -2.02, 0.25]), with evidence of pro-
portional bias between the two matrices. MPPE for 
the comparison of LPS and DPS concentrations was 
-19.8%, and the MAPE was 20.3%.
Table 3. Precision and accuracy for dried urine spots.
 Trimethoprim Sulfamethoxazole
 Intra-run accuracy (%) Intra-run precision (%) Intra-run accuracy (%) Intra-run precision (%)
Run 1
LLOQ 92.7 2.5 96.0 6.1
Low 101.4 2.1 99.5 2.8
Mid 101.5 2.7 99.4 2.5
High 96.3 4.7 99.1 2.4
Run 2
LLOQ 94.0 2.9 95.1 2.9
Low 99.6 1.1 96.3 3.6
Mid 101.3 3.6 97.8 3.7
High 97.4 3.0 97.5 2.3
Run 3
LLOQ 99.3 2.6 97.4 5.1
Low 102.5 3.8 99.6 2.5
Mid 101.7 3.6 99.5 2.2
High 93.0 2.6 96.0 2.5
 Inter-run accuracy (%) Inter-run precision (%) Inter-run accuracy (%) Inter-run precision (%)
LLOQ 95.3 4.0 96.2 4.6
Low 100.6 2.8 97.9 3.2
Mid 100.9 3.1 98.6 2.7
High 95.2 4.4 97.3 2.6
Trimethoprim: LLOQ, 500 ng/ml; low, 1500 ng/ml; mid, 20 μg/ml; high, 200 μg/ml.
Sulfamethoxazole: LLOQ, 1 μg/ml; low, 3 μg/ml; mid, 40 μg/ml; high, 400 μg/ml.
Accuracy and precision were assessed using five determinations per concentration.
Table 4. Percentage recovery for dried plasma spots and dried urine spots.
 Trimethoprim Sulfamethoxazole
 Dried plasma spots Dried urine spots Dried plasma spots Dried urine spots
Extraction recovery (%)
Low QC 103.4 100.7 100.7 97.1
Mid QC 105.8 99.8 106.4 97.9
High QC 104.2 99.3 104.5 98.4
Trimethoprim (DPS): low, 300 ng/ml; mid, 4 μg/ml; high, 40 μg/ml.
Trimethoprim (DUS): low, 1.5 μg/ml; mid, 20 μg/ml; high, 200 μg/ml.
Sulfamethoxazole (DPS, DUS): low, 3 μg/ml; mid, 40 μg/ml; high, 400 μg/ml.
Extraction recovery was assessed using five determinations per concentration.
DPS: Dried plasma spots; DUS: Dried plasma spots.
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Figure 2. Plot of the dried matrix sample to liquid sample concentration ratio versus the mean of the paired 
concentration. (A) Plot of dried plasma spot-to-liquid plasma sample ratios versus the mean of the dried plasma 
spot and liquid plasma sample concentrations. (B)  Plot of dried urine spot-to-liquid urine sample ratios versus the 
mean of the dried urine spot and liquid urine sample concentrations.The dark solid line represents the observed 
mean ratio, and the dashed lines reference the limits of agreement between the samples. 
DPS: Dried plasma spot; DUS: Dried urine spot; LPS: Liquid plasma sample; LUS: Liquid urine sample; 
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DUS-to-LUS analysis
Twenty-one LUS and DUS paired samples were col-
lected from 16 subjects (median [range] age, 13.9 years 
[2.3, 20.1]; weight, 43.2 kg [12.8, 86.0]; TMP dosing, 
3.4 mg/kg/dose [0.6, 8.8] and 6.1 mg/kg/day [0.6, 
17.6]; SMX dosing, 17.0 mg/kg/dose [3.1, 44.0] and 
30.5 mg/kg/day [3.1, 88.1]). One paired SMX sample 
was below the limit of quantification.
The mean TMP DUS to LUS ratio was 0.94 (95% 
CI: 0.81, 1.06), and the limits of agreement were 0.40 
and 1.47. Passing-Bablock regression showed linear 
correlation between the TMP DUS and LUS concen-
trations and exhibited no evidence of proportional or 
systematic bias between the two matrices (slope 0.96 
[95% CI: 0.90, 1.08]; intercept -0.26 [95% CI: -2.78, 
5.21]). The MPPE for the comparison of TMP DUS 
to LUS concentrations was -6.42% and the MAPE 
was 17.52%.
The mean SMX DUS to LUS ratio was 0.81 (95% 
CI: 0.66, 0.97) and limits of agreement were 0.16 and 
1.47. The Passing-Bablock regression showed modest 
agreement between the SMX LUS and DUS concentra-
tions (slope 0.71 [95% CI: 0.58, 0.79]; intercept 1.16 
[95% CI: -1.66, 8.56]), with evidence of proportional 
bias between the two matrices. MPPE for the compari-
son of SMX LUS and DUS concentrations was -18.66% 
and the MAPE was 31.47%.
Conclusion
An accurate, precise and selective method was devel-
oped to detect TMP and SMX in DPS and DUS 
samples. From a clinical trial perspective, the devel-
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Figure 3. Passing-Bablock regression of trimethoprim and sulfamethoxazole dried plasma and urine spots 
versus liquid plasma and urine sample concentrations (gray line represents line of unity; black line is the 
regression line; dashed lines represent 95% CI). (A) Liquid plasma sample versus dried plasma spot concentrations 
for trimethoprim and sulfamethoxazole. (B) Liquid urine sample versus dried urine spot concentrations for 
trimethoprim and sulfamethoxazole. 
DPS: Dried plasma spot; DUS: Dried urine spot; LPS: Liquid plasma sample; LUS: Liquid urine sample; 
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oped dried matrix sampling method has advantages 
over traditional liquid methods because it allows for 
more flexible sample collection and storage, as well as 
reduced sample volumes. In the assay validation pro-
cess, it was determined that three cleansing punches 
and a 6 mm punch size were optimal to prevent punch 
carryover and nonhomogeneity issues. The developed 
method was applied successfully to measure TMP-
SMX in PK samples collected from an opportunis-
tic PK study. The LLOQ of the assay was appropri-
ate (100 ng/ml, DPS TMP; 500 ng/ml, DUS TMP; 
1000 ng/ml, DPS/DUS SMX).
LPS and DPS yield similar concentrations of TMP 
as evidenced by a linear relationship on the scatter 
plot. While similar, however, TMP LPS and DPS con-
centrations were not identical as evidenced by a neg-
ligible deviation in the mean DPS/LPS ratio (0.88) 
and slope of the Passing-Bablock regression (0.93). 
Interpretation of the Passing-Bablock regression indi-
cates that the differences between the two methods 
are both systematic and proportional, such that DPS 
concentrations are systematically lower than LPS 
values throughout the concentration range, but this 
difference is more marked at higher concentrations. 
When a correction factor of 0.88 (mean ratio of DPS/
LPS) is applied to the DPS concentrations, the fit of 
the Passing-Bablock regression is improved slightly 
(slope 1.06, 95% CI: 1.03, 1.1; intercept -0.04, 95% 
CI: -0.08, -0.02). For TMP, DUS and LUS concentra-
tions of TMP were nearly interchangeable. Based on 
these results, dried matrix sampling is an appropriate 
method to assess TMP PK in clinical studies.
For SMX, LPS and DPS matrices yield modest agree-
ment as evidenced by a relatively linear relationship 
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on the scatter plot. However, SMX LPS and DPS 
concentrations deviate slightly from each other as 
evidenced by the mean DPS/LPS ratio and slope of 
the Passing-Bablock regression (0.86). Interpretation 
of the Passing-Bablock regression indicates the pres-
ence of proportional bias such that the relationship 
between DPS and LPS concentrations are more vari-
able at higher concentrations. Application of a correc-
tion factor of 0.81 (DPS concentration was divided by 
the mean ratio of DPS/LPS) improved the fit of the 
Passing-Bablock regression, and proportional bias is 
no longer apparent (slope 1.07, 95% CI: 0.98, 1.14; 
intercept 0.94, 95% CI: -2.49, 0.30). A similar pro-
portional bias was observed with SMX DUS samples, 
and application of a correction factor of 0.81 (mean 
ratio of DUS/LUS) improved the fit of the Passing-
Bablock regression and decreased proportional bias, 
though this bias remains apparent (slope 0.88, 95% 
CI: 0.71, 0.98; intercept 1.43, 95% CI: -2.05, 10.57). 
However, due to the bias and imprecision observed 
between matrices, further study is needed before dried 
matrix sampling can be applied to assess SMX PK in 
clinical studies.
The present findings may be explained by a num-
ber of considerations. The physicochemical prop-
erties of TMP and SMX, and interaction with the 
filter paper, may contribute to differences in drug 
recovery from dried matrix versus liquid samples. 
The possibilities of inadequate recovery have been 
demonstrated with the drug, gabapentin. Its zwit-
terionic properties require special processes of drug 
extraction from the dried matrix as well as cleaning 
thereafter [25]. Previous investigations of everoli-
mus concentrations in DBS also have demonstrated 
a concentration-dependent level of drug extraction 
from the dried matrix [26]. In this study, in the clini-
cal samples analyzed, extraction of drug at low con-
centrations was higher compared with extraction 
of drug at higher concentrations. This finding is 
similar to the proportionality observed in our evalu-
ation of TMP and SMX concentrations, although 
in the method validation there was no evidence of 
concentration-dependent extraction. Proportionality 
has been improved previously by changes in sample 
preparation, including prolonged shaking time and 
ultrasonic vibration, as well as modifying methods 
of sample extraction [27]. Alternatively, we were able 
to demonstrate improvement in proportionality with 
the addition of a mathematical correction factor.
A drug’s degree of protein binding may mediate 
some interactions with the filter paper and the abil-
ity to extract drug from the dried matrix. The dif-
ferential protein binding between TMP (40%) and 
SMX (70%) could potentially explain some of the 
increased variability observed in SMX compared 
with TMP evaluations [28]. Previous investigators 
have demonstrated that the addition of pasteurized 
plasma proteins to the filter paper used in DBS has 
been useful to deactivate the sites of absorption on 
the filter paper, making it easier to extract drug [29]. 
Chemicals also have been used to denature proteins 
and help promote drug extraction [30]. The benefit of 
these processes is the ability to potentially increase 
drug recovery; however, the addition of pasteurized 
proteins or other chemicals to the dried matrix also 
may contribute to matrix effects and interfere with 
the accuracy of the correlation of drug concentra-
tions between liquid and dried plasma matrices.
The method of assessment of comparability has 
been a point of contention and discussion in the 
literature [22,31]. Previous authors have stressed the 
importance of consideration of linearity, normal 
versus nonparametric distribution of the data, and 
the potential for misclassification of method bias 
with the wrong method of comparability [22,31]. The 
methods used in this analysis are thought to be ben-
eficial because of the lack of sensitivity to outliers 
and nonparametric methodology. In addition, the 
Passing-Bablock method has been used in previous 
comparisons of dried and liquid matrices, with good 
and consistent results [22,32]. Use of multiple meth-
ods in this analysis revealed similar findings for each 
drug, thereby confirming the appropriateness of the 
methodology.
Future perspective
Pediatric PK trials are challenging because of the 
limitations surrounding sparse sampling and blood 
volume requirements. Dried matrix sampling is an 
innovative approach to collect PK samples using lim-
ited blood volume. To be successful, dried matrix 
samples must be coupled with a highly sensitive ana-
lytical method (due to small sample volumes). When 
available, dried matrix PK samples can be collected to 
characterize drug disposition in children while mini-
mizing the ethical concerns related to blood sampling 
in this very vulnerable population. Also, because of 
the ease of sample collection and processing with this 
innovative technology, samples can be collected and 
stored more effectively relative to wet matrices. For 
drugs where concentrations in dried matrix samples 
can serve as a surrogate for plasma concentrations, 
collection of DPS/DUS samples alone can be used to 
characterize the PK of drugs in children. DPS sam-
ples have the advantage of avoiding the ‘hematocrit 
effect’ on blood spot homogeneity, matrix effects and 
assay variability, which can be observed with DBS 
sample analysis.
www.future-science.com 1147future science group
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Executive summary
•	 A precise, accurate and reproducible HPLC–MS/MS method was validated and applied to simultaneously 
quantify trimethoprim-sulfamethoxazole in dried plasma spots and dried urine spots samples collected in an 
opportunistic pediatric study.
•	 The LLOQ for trimethoprim was 100 ng/ml in dried plasma spots and 500 ng/ml in dried urine spots samples; 
for sulfamethoxazole, the LLOQ was 1000 ng/ml for both matrices.
•	 Three cleansing punches and a 6 mm punch size were optimal to prevent punch carryover and homogeneity 
issues, respectively.
•	 Dried matrix sampling is an accurate and precise option for evaluation of trimethoprim concentrations in 
pediatric patients.
•	 Optimal bioanalysis conditions must be assessed and the application of this approach must be evaluated in 
clinical trials before there is widespread implementation of dried matrix sampling for drug measurement in 
children.
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